COPD experts tackle key topics in our latest Q&A
We've recently added some quick-fire questions from the COPD Spotlight Webinar on the topic of "Can we avoid inhaled corticosteroid dependence (ICS) in COPD? Time for clarity". The full Q&A can be found here, or select your question below to read our expert's insights.
Professor Wisia Wedzicha and Dr Kai Beeh tackle five frequently asked questions.
A patient receiving triple therapy moves from Global initiative for chronic Obstructive Lung Disease (GOLD) group D to B. Should we re-evaluate this patient every 12 months or leave him/her on triple therapy because inhaled corticosteroid (ICS) dependency was previously shown?
If a patient is in Global initiative for chronic Obstructive Lung Disease (GOLD) group D and is stable on long acting β2 agonist/long-acting muscarinic antagonist (LABA/LAMA), but their eosinophil level is above 300 cells/µL, should we escalate to triple therapy or not?
Is one long acting β2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combination superior to others and why?
Does a high eosinophil count indicate asthma-COPD overlap (ACO)?
Would you measure blood eosinophils in non-frequently exacerbating patients? If yes, would you make a distinction between patients with 0 and 1 exacerbation in your approach?